OGI 6-K
Organigram Global Inc. (OGI)
6-K
2026-09-30
For: 2026-09-30
View Original
Added on
September 30, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number: 001-38885
ORGANIGRAM GLOBAL INC.
(Translation of registrant’s name into English)
145 King Street West, Suite 1400
Toronto, Ontario ,Canada M5H 1J8
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [ X ]
SUBMITTED HEREWITH
Exhibits
| News Release dated September 30, 2026 | |||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ORGANIGRAM GLOBAL INC.
/s/ Greg Guyatt
Greg Guyatt
Chief Financial Officer
Date: September 30, 2026
Organigram Global to Premiere The 2026 OG Investor Session Today at 4:00 p.m. ET on X
The 2026 OG Investor Session features presentations from senior leadership, an inside look at Organigram's operations, and a fireside Q&A
TORONTO--(BUSINESS WIRE)-- September 30, 2026 - Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram") is pleased to announce that the 2026 OG Investor Session will premiere today, September 30, 2026, at 4:00 p.m. ET on the Company's X account at https://x.com/Organigram_Inc.
The session will also be simulcast on Organigram's LinkedIn and YouTube channels.
“We designed this year’s OG Investor Session around the questions we hear most often from investors — where the next phase of growth comes from, how we think about margins and cash generation, and how we intend to allocate capital in the future,” said Max Schwartz, Director of Investor Relations. “Our goal was to go beyond the traditional investor presentation and give shareholders a more direct look at the business today, the people running it, and the opportunities ahead.”
The session includes:
•Presentations from CEO James Yamanaka, CFO Greg Guyatt, and Finn Age Hänsel, President, Rest of World & CSO
•A behind-the-scenes look at Organigram's Canadian operating footprint
•A fireside Q&A session with management
Watch the session at one of the links below:
X Link: https://x.com/Organigram_Inc
LinkedIn Link: https://www.linkedin.com/company/organigram
YouTube Link: https://www.youtube.com/@OrganigramGlobal
A replay will be available afterward at https://www.organigram.ca/investor-day-2026.
ABOUT ORGANIGRAM
Organigram Global Inc. is listed on the NASDAQ Global Select Market and TSX. The Company’s wholly owned subsidiary, Organigram Inc., is a licensed cultivator and processor. Through its acquisition of Sanity Group GmbH ("Sanity Group"), Organigram participates in the German medical cannabis market and other emerging markets within Europe.
Organigram is focused on producing high-quality cannabis for adult consumers, as well as extending the Company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Through its acquisition of Sanity Group, Organigram's European brands include Vayamed, avaay, ZOIKS, Endosane Pharmaceuticals, VAAY, and Grashaus Projects. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and infused pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.
FORWARD-LOOKING INFORMATION
This news release contains forward-looking information. Often, but not always, forward looking information can be identified by the use of words such as "plans", "expects", “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information including expectations regarding market performance, involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of
Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and the risks disclosed in the Company’s most recent annual information form, management’s discussion and analysis, and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
FOR INVESTOR RELATIONS ENQUIRIES
Max Schwartz, Director of Investor Relations
[email protected]
[email protected]
FOR MEDIA RELATIONS ENQUIRIES
Mark McKay, Director of Communications